Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Pyrrolidine orexin receptor ligands: MerckRecent Research Landscape

Chronic sleep disorders and narcolepsy stem from insufficient orexin signaling, which these substituted pyrrolidine scaffolds mitigate through targeted receptor activation. Engineering specific alkyl and cyclic pyrrolidine derivatives ensures high potency and metabolic stability for therapeutic efficacy.

What technical problems is Merck addressing in Pyrrolidine orexin receptor ligands?

Excessive daytime sleepiness

(4)evidences

Deficient signaling at orexin receptors leads to sleep disorders and metabolic instability. Restoring receptor activity addresses the underlying cause of narcolepsy and excessive daytime sleepiness.

Inadequate sleep cycle regulation

(2)evidences

Deficient endogenous activation of orexin receptors leads to sleep-wake cycle instability and narcolepsy. Restoring receptor stimulation addresses the underlying cause of excessive daytime sleepiness.

Excessive daytime sleepiness

(1)evidences

Low endogenous orexin signaling leads to narcolepsy and excessive daytime sleepiness. Restoring receptor stimulation corrects neurological wakefulness deficits.